Loading…
← CockpitCompetitor Analysis › AVLN Avalyn Pharma IncOpen in the cockpit ↗

Avalyn Pharma IncAVLNCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Develops inhaled formulations of approved fibrosis drugs (pirfenidone) to treat idiopathic pulmonary fibrosis with fewer side effects.

Momentum neutral 43
Mkt cap
$1.23B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$14.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-134.1 pp
WACC 13.4%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$27.69
1D-0.8%
1W-12.4%
1M+12.4%
3M-25.4%
6M-1.2%
YTDn/a
1Yn/a
ATR %7.3%
52w lowhigh31.1% off high

What Avalyn Pharma does

Develops inhaled formulations of approved fibrosis drugs (pirfenidone) to treat idiopathic pulmonary fibrosis with fewer side effects.

Has no approved product, so it is funded by share sales while AP01 is tested; any future income would come from selling the drug or licensing it. Because pirfenidone is already approved, the route can lean on its known safety record, but the inhaled form must still prove itself in its own trials.

Products and services

  • AP01 (inhaled pirfenidone, IPF)
  • Pipeline inhaled antifibrotics

Where it sits in the supply chain

  • Biopharma R&D
  • Inhaled drug-delivery reformulation
  • Pulmonary fibrosis clinical development

What could go right

  • Better tolerability driving adoption over oral pirfenidone
  • Approval/launch of AP01

What could go wrong

  • Established oral antifibrotics already prescribed
  • Binary late-stage trial risk

Moat: narrow (IP / patents). Inhaled delivery of a known antifibrotic could reduce systemic toxicity versus oral competitors.

Headquarters: Seattle, Washington, US · Founded: 2019 · Employees: 50

Named competitors

Avalyn Pharma at a glance

Size Avalyn Pharma (AVLN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.23B, the 2099th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.69 on 18 Nov 2026.

Performance Over six months the shares fell 1.2%, against -22.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Capital Return on invested capital runs 134.1 points below its cost of capital (13.4% WACC).

Short interest Short interest is 5.2% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026AVLN 97Peer median 78
Six months, rebased to 100: Avalyn Pharma against the median of its 20 peers (local-currency closes).

Avalyn Pharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$42,000-$29,000
EBITDAn/a-$91.2M-$55.7M
Net incomen/a-$85.2M-$49.7M
Free cash flown/a-$81.8M-$48.5M
Capital expendituren/a$344,000$95,000
Total debt$16.9M$1.67M$0

Quarterly statements and history in the cockpit →

Avalyn Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%-10%0%+10%GPCR300026IDIA000950347850GHRS300204HROW2616300006AMPH24930023326883216884436855301263LBRXAVLN6-month return →1-month return →
Up and to the right = strong over both horizons. Avalyn Pharma is the large dot.

Avalyn Pharma competitors and peer comparison

Head to head with its named competitors (AVLN vs RO.SW vs UTHR)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Avalyn Pharma AVLN$1.23B-1%n/an/an/an/a
Roche RO.SW$381B+21%-1%31%5.7×1.7%
United Therapeutics UTHR$24.6B+2%+2%44%7.1×0.3%

How Avalyn Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Avalyn Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureAVLNPeer medianRank in peer set
1-month return+12.4%-5.4%4th highest of 21
6-month return-1.2%-22.2%5th highest of 21
Distance from 52-week high-31.1%-42.2%6th highest of 21
ROIC minus cost of capital-134.1 pp-6.6 pp2nd lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%13.6×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a

Questions

Who are Avalyn Pharma's main competitors?
Named competitors: Roche (Esbriet) (RO.SW), Boehringer Ingelheim (Ofev) (private or unlisted), United Therapeutics (UTHR). The cockpit's measured peer set (industry) also includes Structure Therapeutics, Inc. Sponsored ADR (GPCR), Tianjin Chase Sun Pharmaceutical (300026.SZ), Idorsia (IDIA.SW), C.Q. Pharmaceutical (000950.SZ), D&D Pharmatech (347850.KS), Sinopep-Allsino Bio Pharmaceutical (688076.SS).
How has Avalyn Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -1.2% against -22.2% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.